Weight Loss Treatment Disclosures Surge on UnderwriteMe Protection Platform

The rapid adoption of GLP-1 weight loss medications is reshaping the protection landscape, with applicant disclosures rising from 0.04% to 1.3% in just two years. For insurers and brokers, this shift highlights the necessity of agile underwriting engines that can process new medical trends without disrupting the immediate "buy-now" outcomes that modern customers expect.

What was announced

Data from UnderwriteMe’s Protection Platform Pulse Report 2026 has revealed a significant surge in the proportion of protection applicants disclosing weight loss treatments. The figures show a jump from 0.04% in 2024 to 1.3% in 2026, a trend driven by the increasing availability of GLP-1 and dual GLP-1/GIP medicines, alongside traditional lifestyle and specialist management services. Notably, 58% of these applicants are sourcing their treatment through private providers rather than public health services.

To address this shift, UnderwriteMe introduced a dedicated weight loss treatment question set on its Protection Platform in November 2025. This update was designed to help advisers capture more accurate information and facilitate immediate decisions. Despite the increase in disclosures, "buy-now" outcomes remain high; the report observed rates of 97.9% for Life Cover and 92.1% for Critical Illness Cover among those disclosing such treatments. However, final underwriting decisions still hinge on the broader health profile, including BMI, treatment history, and how the medication was obtained.

The report also highlighted a gap in consumer understanding. In a survey of 2,000 UK adults, 37% of respondents admitted they did not know how weight loss medication would affect their insurance eligibility. This uncertainty was highest among Baby Boomers at 52%. Meanwhile, Gen Z respondents showed the most concern, with 24% believing that disclosing such medication would make them less likely to be accepted for cover.

"The growth in use of weight loss treatments is a good example of how quickly the protection market needs to respond to changes in medicine and customer behaviour. What's particularly encouraging is that the increase in customer disclosures has not prevented strong buy-now outcomes. The highest observed rates reached 97.9% for Life Cover and 92.1% for Critical Illness Cover, showing that disclosing weight loss treatment does not in itself generally prevent an applicant receiving an immediate outcome."

Andrew Doran, CEO of UnderwriteMe

The companies involved

UnderwriteMe is a prominent technology provider in the life insurance and protection sector, known for its underwriting automation software and its multi-insurer Protection Platform. The company is a wholly owned subsidiary of Pacific Life Re, a global reinsurance firm. UnderwriteMe’s technology is used by a wide range of intermediaries and carriers to streamline the application process, moving away from the traditional, slow manual underwriting methods toward instant, data-driven decision-making.

The firm occupies a central role in the UK protection market, acting as the connective tissue between brokers and insurers. By providing a common platform where multiple insurers can offer real-time quotes based on a single set of underwriting questions, the company has significantly influenced how protection products are distributed and bought in the digital age. Its focus remains on reducing the "protection gap" by making the purchase of life, critical illness, and income protection insurance as frictionless as possible for the end consumer.

What FF News has reported before

FF News has closely followed UnderwriteMe’s evolution and its impact on the protection market. In April 2025, we reported that UnderwriteMe Appoints Andrew Doran as New CEO, a move that signaled a new chapter for the firm’s leadership. We have also covered the platform's expanding ecosystem, such as when The Exeter Launches Life Product on UnderwriteMe’s Protection Platform in June 2025.

The company’s focus on high-velocity underwriting for complex disclosures is a recurring theme in our coverage. In May 2025, we noted that Nine in Ten (90%) Life Cover Applications With Mental Health Disclosures Instantly Accepted on the UnderwriteMe Protection platform. More recently, in October 2026, an UnderwriteMe Report Reveals Surge in Immediate Life Cover for Applicants with Health Conditions, further demonstrating the industry's shift toward automated acceptance for non-standard risks.

What this means from an insurtech perspective

The rise of GLP-1 medications presents a classic challenge for protection underwriting: how to price a rapidly evolving medical intervention that may actually lower long-term mortality and morbidity risks while introducing unknown side effects. For carriers and MGAs, the pressure is on to update legacy rulesets that might otherwise flag these medications as a reason for referral or decline. If incumbents fail to adapt their question sets as UnderwriteMe has, they risk losing market share to more agile competitors who can offer instant terms. For brokers, the data serves as a vital tool to combat consumer "disclosure dread," particularly among younger demographics who wrongly fear that medical proactive-ness will lead to insurance exclusion. This trend reinforces the industry-wide move toward "dynamic underwriting," where software must keep pace with pharmaceutical innovation to maintain customer trust and portfolio growth.